CD79A and acute myeloid leukemia: Exploring this heterogeneity, Bhargava and colleagues showed by immunohistochemistry that the detected level of CD79a on myeloid cells is dependent on the antibody clone used, revealing 30–45% AML cases positive for CD79a using the clones 11D10 and HM57 [37].